Volume 8, Number 5—May 2002
Perspective
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
Table 1
Prechallenge neutralization titers of Ebola virus (EBOV)-vaccinated monkeys
| Nonhuman primate species | No. of animals | Vector | Antigen | Neutralization titersa |
|---|---|---|---|---|
| Cynomolgus | 3 | Replicon | GP | 0, 0, 0 |
| Cynomolgus | 3 | Replicon | NP | 0, 0, 0 |
| Cynomolgus | 3 | Replicon | GP + NP | 0, 0, 10 |
| Cynomolgus | 3 | Replicon | Influenza HA | 0, 0, 0 |
| Cynomolgus | 3 | Vaccinia | GP | 10, 20, 20 |
| Cynomolgus | 3 | Liposome | Inactivated virion | 20, 40, 80 |
| Cynomolgus | 2 | Inactivated virion | 10, 20 | |
| Rhesus | 2 | Inactivated virion | 10b, 20 | |
| Cynomolgus | 2 | None | 0, 0 | |
| Rhesus | 2 | None | 0, 0 |
aImmunoglobulin G enzyme-linked immunosorbent assay, neutralizing antibody (PRNT50) All vaccinated monkeys seroconverted by enzyme-linked immunosorbent assay before challenge.
bAnimal survived challenge.
GP, glycoprotein; NP, nucleoprotein.
Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential